Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
– Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks – – Annexon plans to advance the clinical development of ANX007 in geographic atrophy – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients … [Read more…]
